{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:24:23Z","timestamp":1794029063081,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Rigel Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01751-w","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:38:30Z","timestamp":1763138310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort"],"prefix":"10.1186","volume":"18","author":[{"given":"Jorge","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Krauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Taussig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen WL","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Marzac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"de Botton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"1751_CR1","unstructured":"National Cancer Institute. Cancer stat facts: leukemia \u2014 acute myeloid leukemia (AML). 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html; [accessed March 14, 2025]."},{"issue":"S1","key":"1751_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/01.HS9.0000562500.21650.32","volume":"3","author":"S De Botton","year":"2019","unstructured":"De Botton S, Watts J, Baer M, et al. PS1051 FT-2102, an IDH1 m inhibitor, induces mutation clearance in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) treated in phase 1 dose escalation and expansion study. HemaSphere. 2019;3(S1):475\u20136.","journal-title":"HemaSphere"},{"issue":"8","key":"1751_CR3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.24072","volume":"90","author":"CD DiNardo","year":"2015","unstructured":"DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732\u20136.","journal-title":"Am J Hematol"},{"issue":"2","key":"1751_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1084\/jem.20092506","volume":"207","author":"S Gross","year":"2010","unstructured":"Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339\u201344.","journal-title":"J Exp Med"},{"issue":"3","key":"1751_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225\u201334.","journal-title":"Cancer Cell"},{"issue":"7274","key":"1751_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739\u201344.","journal-title":"Nature"},{"issue":"2","key":"1751_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11899-021-00619-3","volume":"16","author":"H McMurry","year":"2021","unstructured":"McMurry H, Fletcher L, Traer E. IDH inhibitors in AML-promise and pitfalls. Curr Hematol Malig Rep. 2021;16(2):207\u201317.","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"1751_CR8","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.3324\/haematol.2020.263806","volume":"106","author":"C Sargas","year":"2021","unstructured":"Sargas C, Ayala R, Chill\u00f3n MC, et al. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. Haematologica. 2021;106(12):3079\u201389.","journal-title":"Haematologica"},{"issue":"22","key":"1751_CR9","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","volume":"28","author":"P Paschka","year":"2010","unstructured":"Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636\u201343.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1751_CR10","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","volume":"28","author":"G Marcucci","year":"2010","unstructured":"Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28(14):2348\u201355.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1751_CR11","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood.2020010165","volume":"137","author":"M Duchmann","year":"2021","unstructured":"Duchmann M, Micol JB, Duployez N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021;137(20):2827\u201337.","journal-title":"Blood"},{"issue":"12","key":"1751_CR12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"1751_CR13","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/S2352-3026(22)00292-7","volume":"10","author":"JM Watts","year":"2023","unstructured":"Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with Azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial. Lancet Haematol. 2023;10(1):e46\u201358.","journal-title":"Lancet Haematol"},{"issue":"4","key":"1751_CR14","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","volume":"63","author":"JA Caravella","year":"2020","unstructured":"Caravella JA, Lin J, Diebold RB, et al. Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem. 2020;63(4):1612\u201323.","journal-title":"J Med Chem"},{"issue":"13","key":"1751_CR15","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","volume":"7","author":"S de Botton","year":"2023","unstructured":"de Botton S, Fenaux P, Yee KWL, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023;7(13):3117\u201327.","journal-title":"Blood Adv"},{"key":"1751_CR16","volume-title":"capsules, for oral use [prescribing information]","author":"REZLIDHIA\u00ae (olutasidenib)","year":"2024","unstructured":"REZLIDHIA\u00ae (olutasidenib). capsules, for oral use [prescribing information]. South San Francisco, CA: Rigel Pharmaceuticals; April; 2024."},{"issue":"4","key":"1751_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/bjh.19944","volume":"206","author":"S De Botton","year":"2025","unstructured":"De Botton S, R\u00e9cher C, Cortes J, et al. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm. Br J Haematol. 2025;206(4):1121\u20138.","journal-title":"Br J Haematol"},{"issue":"24","key":"1751_CR18","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642\u20139.","journal-title":"J Clin Oncol"},{"key":"1751_CR19","volume-title":"(ivosidenib tablets), for oral use [prescribing information]","author":"TIBSOVO\u00ae","year":"2023","unstructured":"TIBSOVO\u00ae. (ivosidenib tablets), for oral use [prescribing information]. Boston, MA: Servier Pharmaceuticals LLC,; October; 2023."},{"issue":"11","key":"1751_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s11864-024-01264-7","volume":"25","author":"JM Watts","year":"2024","unstructured":"Watts JM, Shaw SJ, Jonas BA. Looking beyond the surface: Olutasidenib and Ivosidenib for treatment of mIDH1 acute myeloid leukemia. Curr Treat Options Oncol. 2024;25(11):1345\u201353.","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"1751_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","volume":"9","author":"J Popovici-Muller","year":"2018","unstructured":"Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300\u20135.","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"1751_CR22","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021;106(3):894\u20138.","journal-title":"Haematologica"},{"issue":"4","key":"1751_CR23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.27231","volume":"99","author":"Y Abaza","year":"2024","unstructured":"Abaza Y, Winer ES, Murthy GSG, et al. Clinical outcomes of hypomethylating agents plus venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers. Am J Hematol. 2024;99(4):606\u201314.","journal-title":"Am J Hematol"},{"key":"1751_CR24","doi-asserted-by":"crossref","unstructured":"Lai CE, Leahy TP, Turner AJ et al. Effectiveness of olutasidenib versus Ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm. Leuk Lymphoma 2025;66(10):1821\u201332.","DOI":"10.1080\/10428194.2025.2514894"},{"key":"1751_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106942","volume":"122","author":"JP Bewersdorf","year":"2022","unstructured":"Bewersdorf JP, Shallis RM, Derkach A, et al. Efficacy of FLT3 and IDH1\/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. Leuk Res. 2022;122:106942.","journal-title":"Leuk Res"},{"key":"1751_CR26","doi-asserted-by":"publisher","first-page":"107331","DOI":"10.1016\/j.leukres.2023.107331","volume":"131","author":"V Khanna","year":"2023","unstructured":"Khanna V, Azenkot T, Liu SQ, et al. Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax\u2009+\u2009hypomethylating agent in adults with acute myeloid leukemia: a multicenter retrospective analysis. Leuk Res. 2023;131:107331.","journal-title":"Leuk Res"},{"issue":"3","key":"1751_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_438662","volume":"44","author":"Y Abaza","year":"2024","unstructured":"Abaza Y, McMahon C, Garcia JS. Advancements and challenges in the treatment of AML. Am Soc Clin Oncol Educ Book. 2024;44(3):e438662.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"1751_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(3):454\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"1751_CR29","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3324\/haematol.2022.281877","volume":"108","author":"Y Yerushalmi","year":"2023","unstructured":"Yerushalmi Y, Shem-Tov N, Danylesko I, et al. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/myelodysplastic syndromes after a first transplantation. Haematologica. 2023;108(7):1782\u201392.","journal-title":"Haematologica"},{"issue":"2","key":"1751_CR30","doi-asserted-by":"publisher","first-page":"300060522107846","DOI":"10.1177\/03000605221078466","volume":"50","author":"CH Lin","year":"2022","unstructured":"Lin CH, Chen TC, Shih YH, et al. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution. J Int Med Res. 2022;50(2):3000605221078466.","journal-title":"J Int Med Res"},{"issue":"11","key":"1751_CR31","doi-asserted-by":"publisher","first-page":"6632","DOI":"10.3390\/curroncol31110490","volume":"31","author":"P Niscola","year":"2024","unstructured":"Niscola P, Gianfelici V, Catalano G, et al. Acute myeloid leukemia in older patients: from new biological insights to targeted therapies. Curr Oncol. 2024;31(11):6632\u201358.","journal-title":"Curr Oncol"},{"issue":"6","key":"1751_CR32","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1097\/HS9.0000000000000572","volume":"5","author":"F Thol","year":"2021","unstructured":"Thol F, Heuser M. Treatment for relapsed\/refractory acute myeloid leukemia. Hemasphere. 2021;5(6):e572.","journal-title":"Hemasphere"},{"issue":"22","key":"1751_CR33","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Ravandi F, O\u2019Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422\u20139.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1751_CR34","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1182\/blood-2023-187584","volume":"142","author":"ES Wang","year":"2023","unstructured":"Wang ES, Jonas BA, Watts JM, et al. Factors impacting response to olutasidenib in patients with mIDH1 acute myeloid leukemia [abstract]. Blood. 2023;142(Suppl 1):6047.","journal-title":"Blood"},{"key":"1751_CR35","doi-asserted-by":"crossref","unstructured":"De Botton S, Yee K, Recher C et al. Molecular characteristics of response to olutasidenib (FT-2102) in patients with relapsed\/refractory mIDH1 acute myeloid leukemia [abstract]. Blood. 2021;138(supplement 1):2351.","DOI":"10.1182\/blood-2021-144912"},{"issue":"suppl 16","key":"1751_CR36","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1200\/JCO.2023.41.16_suppl.7036","volume":"41","author":"JM Watts","year":"2023","unstructured":"Watts JM, Patel PA, Choe S, Bai X, Marchione DM, Stein EM. Clinical and molecular characteristics of patients with AML with an exceptional response to Ivosidenib [abstract]. J Clin Oncol. 2023;41(suppl 16):7036.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1751_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00432-016-2290-5","volume":"143","author":"M Fleischmann","year":"2017","unstructured":"Fleischmann M, Schnetzke U, Schrenk KG, et al. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. J Cancer Res Clin Oncol. 2017;143(2):337\u201345.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"1751_CR38","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the united Kingdom medical research Council AML 10 and 12 trials. Blood. 2001;98(6):1752\u20139.","journal-title":"Blood"},{"issue":"19","key":"1751_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194816","volume":"15","author":"DY Shin","year":"2023","unstructured":"Shin DY. TP53 mutation in acute myeloid leukemia: an old foe revisited. Cancers (Basel). 2023;15(19):4816.","journal-title":"Cancers (Basel)"},{"issue":"25","key":"1751_CR40","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386\u201398.","journal-title":"N Engl J Med"},{"issue":"8","key":"1751_CR41","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","volume":"4","author":"AT Fathi","year":"2018","unstructured":"Fathi AT, DiNardo CD, Kline I, et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1\/2 study. JAMA Oncol. 2018;4(8):1106\u201310.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1751_CR42","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722\u201331.","journal-title":"Blood"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01751-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01751-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01751-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T02:03:09Z","timestamp":1763172189000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01751-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1751"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01751-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by independent institutional review boards of each participating site and was conducted in accordance with the ethics principles of the Declaration of Helsinki and with Good Clinical Practice guidelines defined by the International Conference on Harmonization. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jorge Cortes: Research funding for his current or former institution from, and is a consultant to, Astellas, Amphivena, BMS, Novartis, Pfizer, Takeda, Daiichi, Jazz Pharmaceuticals, Merus, and Forma Therapeutics; and is a consultant to Rigel, BiolineRx, Bio-Path, Sun Pharma, and Tern. Antonio Curti: Board\/advisory committee member for Jazz Pharmaceuticals, Pfizer, Novartis, Servier, and AbbVie. Pierre Fenaux: No disclosures. Brian Jonas: Consultancy\/advisory role for AbbVie, BMS, Gilead, Kura, Rigel, Schrodinger, Syndax, and Treadwell; data monitoring committee for Gilead; research funding to institution from AbbVie, Amgen, Aptose, AROG, Biomea, BMS, Celgene, Forma, Forty-Seven, Genentech\/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, and Treadwell. Jurgen Krauter: No disclosures. Pau Montesinos: Consultant and has received research funding from Servier and Bristol Myers Squibb. Christian Recher: Consultant to, has received honoraria and research funding from, and is a board\/advisory committee member for AbbVie, BMS, and Jazz Pharmaceuticals; has received honoraria and research funding from and is a board\/advisory committee member for Amgen and Astellas; is a board\/advisory committee member for Novartis, Pfizer, and Takeda; and is a consultant to, has received honoraria from, and is a board\/advisory committee member for Servier. David C Taussig: Research funding from Bayer and from AbbVie to attend the American Society of Hematology meeting; supported by the National Institute for Health and Care Research (NICR) Royal Marsden\/Institute of Cancer Research Biomedical Research Centre. Eunice Wang: Consultancy fee from AbbVie, Astellas, BMS, Gilead, GSK, Jazz, Kite, Novartis, Pfizer, PharmaEssentia, Takeda. Speaker bureau for Astellas, Kite, Novartis, Pfizer, Dava Oncology and Kura Oncology. Justin Watts: Research funding from and was a board\/advisory committee member for Takeda; has received research funding from Immune System Key Ltd; and is a consultant or board\/advisory committee member for Genentech, Rafael Pharma, Reven Pharma, Celgene\/Bristol-Myers Squib, Servier, Rigel, Aptose, Astellas, and Daiichi-Sankyo. Andrew Wei: Serves on advisory boards for Janssen, Abbvie, Servier; has consulted for Servier, JNJ, Aculeus, receives research funding to the Institution from Novartis, Storm Therapeutics, Abbvie, Servier, BMS, Janssen, Syndax, Astra Zeneca; serves on speaker bureaus for Abbvie, Servier; A.H.W is an employee of the Walter and Eliza Hall Institute (WEHI). WEHI receives milestone and royalty payments related to the development of Venetoclax. Current and past employees of Walter and Eliza Hall Institute may be eligible for financial benefits related to these payments. A.H.W. receives such a financial benefit. Karen WL Yee: Consultant for Bristol Myers Squibb\/Celgene, F. Hoffmann-La Roche, GSK, Jazz Pharmaceuticals, Novartis, Pfizer, Shattuck Labs, Taiho Oncology, and Takeda; received research funding from Astex Pharmaceuticals, Forma Therapeutics, F. Hoffmann-La Roche, Forma Therapeutics, Genentech, Geron Corporation, Gilead Sciences, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novartis, and Treadwell Therapeutics; and received honoraria from AbbVie, TaiHo, and Novartis. Hua Tian: Employment and stock ownership, Rigel Pharmaceuticals. Aaron Sheppard: Employment and stock ownership, Rigel Pharmaceuticals. Christophe Marzac: Honoraria from Astellas, Jazz Pharmaceuticals, Incyte; Research funding from Incyte. Stephane de Botton: Honoraria from AbbVie, Astellas Pharma, Bristol Myers Squibb, Jazz Pharmaceuticals, and Servier; has acted as a consultant or advisor to Bristol Myers Squibb, GlaxoSmithKline, Servier, and Syndax; has participated in speaker bureaus for AbbVie, Astellas Pharma, Bristol Myers Squibb, Jazz Pharmaceuticals, and Servier; has received research funding to his institution from Auron Therapeutics and Forma Therapeutics; and has received travel, accommodations, or expenses from AbbVie and Servier.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}